

## Laufende Klinische Versuche

Diagnosis	Study Title	Study Name / Product /Implimentation	Sponsor	Principal Investigator	Sub- Investigator	Status / Start / End
Metastatic Melanom	<b>Columbus CMEK162B2301</b>	A Phase III randomized, 3-arm, open label, multicenter study of <b>LGX818</b> plus <b>MEK162</b> and LGX818 monotherapy compared with <b>Vemurafenib</b> in patients with unresectable or metastatic BRAF V600 mutant melanoma	Novartis	Prof. Hunger	Dr. Lamos / Prof. Schlapbach	closed to recruitment / follow-up, not archived
Hidradenitis	<b>CAIN357M2301 Sunshine</b>	A randomized, double-blind, short /long-term efficacy /adult <b>patients with moderate to severe HS</b>	Novartis	Prof. Hunger	Dr. Pelloni / Dr. Morteza	recruiting
Resected Stage II melanoma	<b>MK-3475-716</b>	Adjuvant Therapy with Pembrolizumab versus Placebo in <b>Resected Stage II Melanoma: A Randomized, Double-Blind Study (Keynote716)</b>	MSD	Prof. Hunger	Dr. Lamos	recruiting
Metastatic Melanom	<b>CA045-001</b>	A Phase 3, Randomized, Open-Label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participans with Previously Untreated <b>Unresectable or Metastatic Melanoma</b>	Bristol-Myers Squipp GesmbH	Prof. R. Hunger	Dr. Lamos	recruiting
Basal cell carcinoma	<b>NISSO</b>	A non-interventional, multi-national, multi-center post-authorization safety study (PASS) to assess the <b>long-term safety and tolerability of Odomzo® (sonidegib)</b> administered in patients with locally <b>advanced basal cell carcinoma (laBCC) - NISSO</b>		Prof. Hunger		recruiting
Acne	<b>IIT Teledermatology</b>	randomized Open-Label Trial Comparing Teledermatology vs. Face-to-face Consultation in the Follow-Up o Patients with Mild-to-Moderate Acne. Teledermatology in the Follow-Up of Patients with <b>Mild-to-Moderate Acne.</b>	Galderma	Prof. R. Hunger		recruiting
Cosmetic Compatability	<b>MIBELLE</b>	Epicutaneous <b>Testing of Cosmetic products</b> to Determine Skin Compatibility	Mibelle AG	Prof. Simon /Allergy laboratory	Dr. Bürgler	closed to recruitment
Atopic Dermatitis	<b>I4V-MC-JAHM</b>	A multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Study to evaluate the Efficacy and Safety of <b>Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis.</b>	Lilly	Prof. Simon		closed to recruitment
Atopic Dermatitis	<b>I4V-MC-JAIN</b>	A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-controlled Study Evaluating the <b>Safety and Efficacy of Baricitinib in combination with Corticosteroids</b> in Adult Patients with Moderate to severe Atopic Dermatitis who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine	Lilly	Prof. Simon		closed to recruiting

<b>Atopic Dermatitis</b>	<b>I4V-MC-JAHN Addendum</b> (Fortsetzung JAHM)	A Phase 3 Multicenter, Double-Blind Study to Evaluate the <b>Long-Term Safety and Efficacy of Baricitinib</b> in Adult Patients with Atopic Dermatitis	Lilly	Prof. Simon		closed to recruiting
<b>Atopic Dermatitis</b>	<b>M16-045</b>	A Phase III randomized, placebo-controlled, double-blind study to evaluate <b>Upadacitinib</b> in Adolescent and Adult Subjects with <b>moderate to severe Atopic Dermatitis</b>	Abbvie	Prof. Simon / CTU Bern	Dr. Schlapbach, Dr. Fässler	recruiting
<b>Atopic Dermatitis</b>	<b>C3291037</b>	A phase 3b/4, Multicenter, Randomized, Assor Blinded, Vehicle and Active Controlled, Parallel Group Study of the Efficacy, Safety and local Tolerability of <b>Crisaborole Ointment, 2%</b> in Pediatric and Adult subjects with <b>mild to moderate Atopic Dermatitis</b>	Pfizer	Prof. Simon	Dr. Fässler, Dr. Impstef	recruiting
<b>Atopic Dermatitis</b>	<b>LPS 15497</b>	A randomized double blind placebo controlled study <b>evaluating the effect of Dupilumab on sleep</b> in adult patients with moderate and severe atopic dermatitis	Sanofi	Prof. Simon	Dr. V. Impstef	recruiting
<b>Autoimmun bullöse Hauterkrankung</b>		<b>Bestimmung</b> der besten <b>Entnahmestelle</b> der direkten Immunfluoreszenz (DIF) für die Diagnose einer autoimmunbullösen Hauterkrankung	Inselspital	Prof. Borradori	Dr. Häfliger	recruiting
<b>Psoriasis</b>	<b>Aprescalp</b>	A phase 4 multicenter, randomised, placebo-controlled study evaluating the <b>effect of Apremilast on pruritus</b> and quality of life of patients with <b>moderate-to-severe scalp Psoriasis</b>	Uni-B+D3:D7 Basel	Prof. Yawalkar	Dr. Heidemeyer, Dr. Morteza	recruiting
<b>Psoriasis</b>	<b>VALUE</b>	Multi-Country Prospective Observational, Cohort Study of Patients with Moderate to Severe chronic Plaquel Psoriasis	AbbVie	Prof. Yawalkar	Dr. K. Heidemeyer Dr. V. Emelianov Dr. M. Jafari	recruiting

## Laufende Forschungsprojekte

Diagnosis	Study Title	Study Name / Product /Implimentation	Sponsor	Principal Investigator	Sub- Investigator	Status / Start / End
Oraler Lichen planus	<b>Oral lichen planus versus oral lichenoid lesions</b>	Oraler Lichen planus und orale lichenoid Läsionen; eine klinische Untersuchung zur Differentialdiagnose & Charakterisierung.d.Krankheitsverlaufs	Inselspital Bern	Prof. Beltraminelli	PD Dr.med. L. Feldmeyer	läuft seit 2010 / Ende 2020
melanozytäre Läsionen	<b>LTML-Projekt</b>	Histologische Charakteristiken von melanozytären Läsionen an den Beinen		Prof. Beltraminelli		läuft seit 2018 / Ende 2020
Psoriasis vulgaris		Identification of inflammatory and immune cell function in psoriasis	Inselspital Bern	Prof. Yawalkar	Prof. Schlapbach, Dr. Heidemeyer	läuft
Genodermatoses	<b>Genetische Untersuchung zu erblichen Hauterkrankungen</b>	Identifizierung der kausalen genetischen Varianten in Patienten mit ungeklärten Genodermatosen, insbesondere palmoplantarem Keratoderm. Gewinn neuer Erkenntnisse zur Genotyp-Phänotyp Korrelation und zur Funktion von Genen in der Haut. Multizentrische Studie: Basel und Bern Universitätsspital.	Dr. Bettina Burger (Basel)	Dr. Gouveia		Nov 2015 - Dec 2019
Chronic inflammatory skin disease		Skin immunity and barrier function in infalmmatory skin diseases		Prof. Simon		
Tumor-Immunität	<b>Th9 cells in human melanoma</b>	Characterizing human T helper type 9 cells and their role in anti-melanoma immune response		Prof. Schlapbach		läuft
cutaneous wart	<b>Neoangiogenesis in cutaneous wart</b>			Prof. Hunger / Dr. Bossart		läuft
Epitope spreading in pemphigus	<b>PEGASUS</b>	Epitope spreading in pemphigus (TP7 of FOR 2497 Pegasus project)	IIT	Prof. Borradori		läuft
Basal cell carcinoma		Basal cell carcinoma associated to dermatofibroma; induction phenomenon or true tumor?		PD Dr. med. L. Feldmeyer		läuft
		Difining the molecular landscape of cancer-associate stroma in cutaneous squaous cell carcinoma in clinical specimen		PD Dr. med. L. Feldmeyer		läuft
Cutaneous pigmentation		Cutaneous pigmentation after paravenous iron injection treated with Q-switched lasers; a retrospective study		Dr. K. Heidemeier		

## Datenbanken

Diagnosis	Study Title	Study Name / Product /Implimentation	Sponsor	Principal Investigator	Co- Investigator	Status / Start / End
Dermatitis		Clinical epidemiology on contact allergen sensitization and allergic contact dermatitis. IVDK	Inselspital Bern	Dr. Simon	Regina Allergielabor	läuft 2007 - 2030

## Klinische Versuche in Vorbereitung

Diagnosis	Study Title	Study Name / Product /Implimentation	Sponsor	Principal Investigator	Co- Investigator	Status / Start / End
Melanoma	2125-MEL-301	A randomized phase 3 comparison of IMO-2125 with Ipilimumab versus Ipilumab alone in subjects with Anti-PD-1 refractory Melanoma	Idera	Prof. Hunger		awaiting opening
Metastatic Melanoma	PSV Array 818-103	Encorafenib and Binimetinib	Array	Prof. Hunger		
Hidradenitis	HS0003	Phase III Clinical Study in Adult Subjects with <b>Hidradenitis Suppurativa</b>	Parexel	Prof. Hunger		awaiting opening
Bulloid Pemphigoid		Phase 3, multicenter, placebo-controlled, Clinical Trial in Bullous Pemphigoid (BP)	bioskin	Prof. Borradori	Dr. Radonjic	2021 - 2022
Atopic Dermatitis	20170755	Atopic Dermatitis study- Feasability & new Systemic Lupus Erythematosus study	Amgen	Prof. Simon		awaiting opening
Atopische Dermatitis	TREAT	Register	Sanofi	Prof. Simon		
Prurigo Nodularis	RD.06.SPR.203065	A randomized, Double-blind, Placebo-Controlled Study to assess the Efficacy and Safety of Nemolizumab (CE14152) in Subjects wit Prurigo Nodularis	Gelderma	Prof. Simon		

<b>Hypereosinophilic Syndrome (HES)</b>	<b>D3254X00001</b>	A Multicentre, Randomized, Double-blind, Parallel-group, Placebo-Controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with HES	AstraZeneca	Prof. Simon		
<b>Produkttest</b>		Sterile vs. non-sterile gloves for the incidence of infections after minor surgery (GLOVES)	Della Torre	Dr. Della Torre	Dr. Canzzaniga	
<b>Urticaria</b>		A Double-Blind, Randomized, Active-controlled, Parrallel Group, Phase 3 Study to Compare Efficacy, Pharmacokinetics and Safety of IP and EU-approved Xolair in Patients withChronic Idiopathic/Spontaneous Urticaria who remain Symptomatic Despite H1-antihistamine Treatment.	iqvia	Prof. Simon		
<b>Hidradenitis suppurativa</b>		IIT 110073 A single-blind, randomized trial	Gelderma IIT	Prof. Hunger	Dr. M. Jafari	
<b>Melanoma</b>	<b>57002000 Bering</b>	Encorafenib + Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma; a multi-centric, national, prospective, longitudinal, non-interventional study in Switzerland	Bering	Prof. Hunger	Dr. Lamos Dr. Bossart	awaiting opening